Bacterial expression and characterization of human recombinant apolipoprotein(a) kringle IV type 9

被引:2
作者
Chung, FZ
Wu, LH
Lee, HT
Mueller, WT
Spahr, MA
Eaton, SR
Tian, Y
Settimi, PD
Oxender, DL
Ramharack, R
机构
[1] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Vasc & Cardiac Dis, Ann Arbor, MI 48105 USA
[2] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Biol Mol, Ann Arbor, MI 48105 USA
[3] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Med Chem, Ann Arbor, MI 48105 USA
关键词
D O I
10.1006/prep.1998.0898
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Elevated plasma lipoprotein(a) [Lp(a)] is an independent risk factor for several vascular diseases. Lp(a) particles are generated through the formation of a disulfide bond between Cys(4057) of kringle TV type 9, (KIVt9), of the multikringle apolipoprotein(a) [apo(a)] and a cysteine in apoB-100 low-density Lipoprotein (LDL). To better understand this interaction, we have expressed and purified KIVt9 from Escherichia coli as a His-Tag fusion protein. Dithiothreitol (DTT)-treated purified KIVt9 migrated as a single similar to 17.3-kDa band on SDS-PAGE gels. Without DTT, an additional band twice the molecular weight of KIVt9 was observed. The double-size band presumably resulted hom dimerization of individual kringles, through their unpaired cysteine residues, since a mutation Cys(4057) -->Ser ([Ser(4057)]KIVt9) abolished dimer formation. Using a gel-shift assay, we showed that KIVt9 could couple to 14-amino-acid apoB-100 synthetic peptides (apoB(3732-3745) and apoB(4319-4332)) containing Cys(3734) or cys(4326). Both Of these apoB-100 cysteines have been reported to associate with apo(a) to generate Lp(a). In the presence of either apoB-100 peptide, KIVt9 was shifted to a higher molecular weight that was consistent with the covalent addition of a 1.2-kDa apoE-100 peptide. Identical apoB-100 peptides in which the cysteine residues were replaced by alanine ([Ala(3734)]apoB(3732)-(3745) and [Ala(4326)]apo(B4319-4332)) had no effect in the gel-shift assay. Furthermore, [Ser(4057)]KIVt9 did not covalently interact with apoB(3732-3745) or apoB(4319-4332) These results indicated that KIVt9 couples to the Cys-apoB-100 peptides through a disulfide linkage. This system may be suitable for further investigating the apo(a)/apoB-100 coupling reaction and the structure of KIVt9 through X-ray crystallographic studies. (C) 1998 Academic Press.
引用
收藏
页码:222 / 228
页数:7
相关论文
共 17 条
  • [1] SITE-SPECIFIC MUTAGENESIS DEMONSTRATES THAT CYSTEINE-4326 OF APOLIPOPROTEIN-B IS REQUIRED FOR COVALENT LINKAGE WITH APOLIPOPROTEIN(A) IN-VIVO
    CALLOW, MJ
    RUBIN, EM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (41) : 23914 - 23917
  • [2] CHEN SH, 1986, J BIOL CHEM, V261, P2918
  • [3] INHIBITORS FOR THE IN-VITRO ASSEMBLY OF LP(A)
    FRANK, S
    DUROVIC, S
    KOSTNER, K
    KOSTNER, GM
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (10) : 1774 - 1780
  • [4] CARBOXYL-TERMINAL TRUNCATION OF APOLIPOPROTEINB-100 INHIBITS LIPOPROTEIN(A) PARTICLE FORMATION
    GABEL, B
    YAO, ZM
    MCLEOD, RS
    YOUNG, SG
    KOSCHINSKY, ML
    [J]. FEBS LETTERS, 1994, 350 (01) : 77 - 81
  • [5] Lipoprotein(a) assembly - Quantitative assessment of the role of apo(a) kringle IV types 2-10 in particle formation
    Gabel, BR
    May, LF
    Marcovina, SM
    Koschinsky, ML
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (12) : 1559 - 1567
  • [6] ACTIVATION OF TRANSFORMING GROWTH-FACTOR-BETA IS INHIBITED IN TRANSGENIC APOLIPOPROTEIN(A) MICE
    GRAINGER, DJ
    KEMP, PR
    LIU, AC
    LAWN, RM
    METCALFE, JC
    [J]. NATURE, 1994, 370 (6489) : 460 - 462
  • [7] PROPOSED MECHANISMS FOR BINDING OF APO(A) KRINGLE TYPE-9 TO APO-B-100 IN HUMAN LIPOPROTEIN(A)
    GUEVARA, J
    SPURLINO, J
    JAN, AY
    YANG, CY
    TULINSKY, A
    PRASAD, BVV
    GAUBATZ, JW
    MORRISETT, JD
    [J]. BIOPHYSICAL JOURNAL, 1993, 64 (03) : 686 - 700
  • [8] APOLIPOPROTEIN(A) - EXPRESSION AND CHARACTERIZATION OF A RECOMBINANT FORM OF THE PROTEIN IN MAMMALIAN-CELLS
    KOSCHINSKY, ML
    TOMLINSON, JE
    ZIONCHECK, TF
    SCHWARTZ, K
    EATON, DL
    LAWN, RM
    [J]. BIOCHEMISTRY, 1991, 30 (20) : 5044 - 5051
  • [9] KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819
  • [10] Koschinsky ML, 1996, CURR PHARM DESIGN, V2, P121